You are here

FDA Approves Broader Label for ALS Drug, Riluzole

Different route of administration added

ITF Pharma has been approved to broaden the existing label for Tiglutik (riluzole) oral suspension to include administration via percutaneous endoscopic gastrostomy tubes for the treatment of amyotrophic lateral sclerosis, sometimes called Lou Gehrig's disease.

Riluzole is the gold standard of treatment to slow the progression of ALS. While the mechanism of action of riluzole is not fully understood, in clinical studies it has been shown repeatedly to modulate glutamate neurotransmission by inhibiting both glutamate release and postsynaptic glutamate receptor signaling.

The FDA approval is based on a study that showed Tiglutik was bioequivalent when administered intragastrically and orally.

In clinical studies, the most common side effects were oral hypoesthesia, asthenia, nausea, decreased lung function, hypertension and abdominal pain.

Source: ITF Pharma, December 13, 2019

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs